Drug Trial Radar · NCT04144517
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Feb 5, 2020
Primary completion
Oct 8, 2021
Study completion Jan 7, 2022
Sponsor
- Lead sponsor
- Mural Oncology, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Immune Oncology Network (ION)
- First posted
- Oct 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.
Conditions
- Squamous Cell Carcinoma of Head and Neck
Interventions
Nemvaleukin AlfaDrug
Nemvaleukin alfa IV infusion.
PembrolizumabDrug
Pembrolizumab IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) Based on RECIST v1.1Time frame: From the first dose of study drug until first PD or death, whichever occurred first (up to 49 weeks)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Mural Oncology Investigational Site
Miami, Florida
Mural Oncology Investigational Site
Atlanta, Georgia
Mural Oncology Investigational Site
Minneapolis, Minnesota
Mural Oncology Investigational Site
New York, New York
Mural Oncology Investigational Site
New York, New York
Mural Oncology Investigational Site
Cleveland, Ohio
Mural Oncology Investigational Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.